Cats and humans, unlike most rodent species, develop amyloid in the islets of Langerhans in conjunction with non-insulin-dependent diabetes mellitus. The amyloid consists of a 37-amino acid polypeptide referred to as islet amyloid polypeptide (IAPP). The primary structures of IAPP from human and three rodent species have previously been determined. Sequence divergence was seen in the region corresponding to amino acid residues 20-29, which in human IAPP has been suggested to confer the amyloidogenic properties to the molecule. Using polymerase chainreaction methodology, we determined the primary sequence of cat IAPP. Amino acid region 20-29 shows specific similarities and differences compared with human and rodent IAPP, respectively. A synthetic cat IAPP 20 _2 9 decapeptide formed amyloid fibrils spontaneously in vitro. Comparison between the structure and amyloid fibril-forming activity of various synthetic peptides suggests that the amino acid residues at positions 25-26 in mature IAPP are important for the amyloidogenic properties of the molecule. Diabetes 39: 1990 A myloid deposits in the islets of Langerhans are a typical finding in association with non-insulin-dependent (type II) diabetes mellitus in humans and cats (1-5). The amyloid is composed predominantly of islet amyloid polypeptide (IAPP; also referred to as amylin or diabetes-associated peptide), a 37-amino acid polypeptide showing partial sequence identity with members of the calcitonin gene-related peptide (CGRP; 6-9), but pro-IAPP immunoreactivity has also been recently demonstrated in human islet amyloid deposits (10). cDNA cloning of human IAPP has indicated that the 37-amino acid peptide is a normal proteolytic product of an 89-amino acid precursor that is amidated at the COOH-terminal (11-13). Its normal physiological function is not known, but its homology with the CGRPs, its colocalization with insulin in islet (3-cell secretory granules (14, 15) , and its proposed function as an inhibitor of insulin-stimulated uptake of glucose in skeletal muscle cells (16) all point to a role as a hormone.
pro-IAPP immunoreactivity has also been recently demonstrated in human islet amyloid deposits (10) . cDNA cloning of human IAPP has indicated that the 37-amino acid peptide is a normal proteolytic product of an 89-amino acid precursor that is amidated at the COOH-terminal (11) (12) (13) . Its normal physiological function is not known, but its homology with the CGRPs, its colocalization with insulin in islet (3-cell secretory granules (14, 15) , and its proposed function as an inhibitor of insulin-stimulated uptake of glucose in skeletal muscle cells (16) all point to a role as a hormone.
The significance of islet amyloid formation in the pathogenesis of type II diabetes remains controversial, due at least in part to the fact that islet amyloid also occurs in conjunction with increasing age in nondiabetic humans and cats (1) (2) (3) 5) . However, islet amyloid deposits in nondiabetic individuals are not as extensive as those of diabetic individuals (2, 3, (17) (18) (19) . Localization of amyloid in very close contact with the p-cells, interposed between p-cells and islet capillaries (20, 21) , suggests that some of the aberrations in p-cell function observed in type II diabetes are caused by the amyloid deposits per se (22) .
Also of interest is the species-specific occurrence of the islet amyloid-diabetes mellitus syndrome. Humans, monkeys, and cats develop islet amyloid-type II diabetes syndromes that are similar regarding age dependency and spontaneous onset (1) (2) (3) (4) (5) 23) . In contrast, most rodent species and dogs (which are known to produce IAPP) do not develop islet amyloid and also do not develop characteristic type II diabetic syndromes (14) .
A region corresponding to amino acid residues 20-29 of the human IAPP molecule has been shown to have an intrinsic capacity of forming amyloid fibrils in vitro (13, 24) . We recently showed that the IAPP molecules of three rodent species (which do not develop islet amyloid) diverge substantially from the human sequence in this region (25) . We also showed that a synthetic peptide corresponding to amino acid region 20-29 of hamster IAPP lacked the ability to form amyloid fibrils in vitro (25) .
In this study, with polymerase chain-reaction (PCR) meth- odology, we determined the cat lAPP sequence. Consistent with the high incidence of islet amyloid formation observed in this species, amino acid region 20-29 was similar in structure to the corresponding human region, and a cat IAPP 20 _ 29 synthetic peptide formed amyloidlike fibrils in vitro.
A cat/hamster IAPP 20 _29 hybrid peptide also formed amyloidlike fibrils in vitro, suggesting that the amyloidogenic properties of lAPP are dependent on the amino acid residues at positions 25 and 26.
RESEARCH DESIGN AND METHODS
Cat lAPP cDNA cloning by PCR. Cat pancreas total cellular RNA was prepared, converted to single-stranded cDNA, and used as template for enzymatic DNA amplification by PCR (26) as described previously (25) . The two oligonucleotide primers employed in the reaction, 5'GCAAGCTTAGTCAT-CAGGTGGAAAAGCG and 5'CGGAATTCTCTACTGCATTC-CTCTTGC, were synthesized with Applied Biosystems equipment (Forster City, CA). Amplification products of expected size were isolated, subcloned into M13 derivatives, and sequenced as described previously (27) . In vitro test for amyloid fibril-forming activity of synthetic lAPPs. This was performed as described previously (13) . Briefly, decapeptides corresponding to amino acid residues 20-29 of cat lAPP and cat/hamster lAPP were synthesized by automated solid-phase technique on an Applied Biosystems model 430A peptide synthesizer. The peptides were purified by reverse-phase high-performance liquid chromatography and analyzed by mass spectrometry (28) . The peptides were solubilized (5 mg/ml) in 10% NH 4 OH, and 50% acetic acid was slowly added to the clear solution until a gel was formed. Aliquots of this material were dried on glass slides, stained with Congo red, and analyzed by polarization microscopy. Small droplets were also applied to formvar-coated copper grids, negatively contrasted with uranyl acetate, and studied in a Jeol 100-SX electron microscope at 80 kV. -N H * -N H 2 -N H *
RESULTS
Isolation of cat IAPP cDNA fragment by PCR. Due to the presumed low abundance of cat IAPP mRNA in the total pancreas mRNA preparation, we utilized PCR methodology instead of classic cDNA library construction and screening procedures. We have previously employed this technique to determine the IAPP sequence of three rodent species (25) . The primers used were directed against the human IAPP cDNA sequence and were expected to be homologous enough with other mammalian IAPP sequences to allow amplification (11-13). To compensate for possible mismatches, we reduced the annealing temperature of the first two PCR cycles to 37°C (26) . Figure 1 shows the principle for the amplification reaction. An amplification product of expected size (168 base pairs) was agarose gel purified, restriction enzyme digested, subcloned into M13 vectors, and sequenced. The resulting cat IAPP cDNA sequence is shown in comparison with the human, hamster, rat, and mouse sequences (Fig. 2) . Specific sequence divergence in amyloidogenic region of IAPP. We compared the IAPP amino acid sequences from species studied to date (Fig. 3) . A substantial variability is observed in amino acid region 17-29. The only positions that are consistently linked with the occurrence of islet amyloid formation are residues 25 and 26, i.e., Ala-lie in cat and human (which develop islet amyloid) and Pro-Val in hamster, rat, and mouse (which do not develop islet amyloid).
In vitro amyloidogenic properties of synthetic amino acid regions 20-29.
A synthetic peptide corresponding to cat IAPP amino acid residues 20-29 formed amyloidlike fibrils in vitro exhibiting green birefringence on Congo red staining and polarization microscopy (not shown). Electron microscopy showed that the fibrils were long and slightly curved and consisted of two or more parallel filaments of ~4 nm width (Fig. A A) . The cat IAPP amino acid region 20-29 differs from the corresponding hamster region in three positions, 20, 25, and 26 ( Fig. 3) . To test the importance of positions 25 and 26 in fibrillogenesis, we synthesized a hamster IAPP 20 _ 2 9 peptide, with the Pro-Val sequence at positions 25 and 26 replaced by the respective residues (Ala-lie) found in human and cat IAPP. This cat/hamster hybrid peptide exerted fibrillogenic properties closely similar to those of the cat IAPP 20 _29 peptide (Fig. 4, B and C) . Data obtained concerning the structure and in vitro fibrillogenic properties of different IAPP amino acid regions 20-29 are summarized in Table 1 .
DISCUSSION
Two central questions regarding islet amyloid in type II diabetes remain essentially unanswered: What is the cause of amyloid formation? What role does amyloid play in the pathogenesis of type II diabetes? This study provides an important clue regarding the differences in islet amyloid formation between certain mammalian species. However, the conclusions obtained obviously depend on whether the in vitro amyloidogenic properties of the respective synthetic decapeptide studied (corresponding to amino acid residues 20-29 of the mature IAPP molecule) truly reflect the amyloidogenic properties of the intact 37-amino acid IAPP molecule or its precursor in vivo. The structure of IAPP has been determined either by direct chemical analysis or cDNA analyses in five mammalian species (6-9,11-13,25,29, herein) , and a correlation between the in vitro behavior of synthetic IAPP 20 -29 peptides and the observed in vivo incidence of islet amyloid formation has been demonstrated. The data point to specific differences in the IAPP primary structure, especially amino acid residues at positions 25 and 26, as potential determinants of the observed species differences. However, differences in primary sequence cannot explain quantitative differences in islet amyloid formation between human individuals. The human IAPP structure, deduced through the sequencing of cDNA and genomic DNA clones from individuals apparently without islet amyloid deposits (12,13,30, unpublished data) , is identical to that obtained by sequencing IAPP isolated from islet or insulinoma amyloid (6-9). Thus, although a specific primary structure of IAPP may be Table 1 for peptide sequences). A: wide aggregates (up to 27 nm width) of filaments formed from cat IAPP20_29. B: similar aggregates formed from hamster/cat hybrid IAPP20-29-C: slender fibrils consisting of s2 filaments, each ~4 nm wide. Congophilia and green birefringence with polarized light (characteristic feature of amyloid) were observed when fibrils in A-C were exposed to Congo red dye. x 110,000.
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a prerequisite for amyloidogenesis, other factors must also be involved in determining whether islet amyloid will form. These factors are not known, but may include aberrations in synthesis, processing, release, or paracellular clearance of IAPP (31) .
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